SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Todd N. Weisrock who started this subject2/19/2001 10:03:06 AM
From: nigel bates   of 411
 
A little out of date....
5 December 2000 - Cyclacel Limited, the UK-based cancer therapeutics company, today announced a collaboration agreement with CV Therapeutics, Inc. (Nasdaq: CVTX) of Palo Alto, California.
Under the terms of the collaboration Cyclacel will screen a library of small molecule compounds developed by CVT in Cyclacel's proprietary assays and determine their potential to inhibit the cancer cell cycle. The agreement provides Cyclacel with an option to negotiate an exclusive world-wide licence to develop and commercially exploit selected compounds in the field of proliferative diseases. CVT has an option to join Cyclacel in clinical development of selected compounds and exploit them in the Americas at the beginning of Phase II or the beginning of Phase III under which Cyclacel and CVT would pay each other royalties and certain milestone payments.
Spiro Rombotis, Cyclacel's Chief Executive, said: "The agreement with CV Therapeutics validates Cyclacel's global reputation as a leader in cell cycle chemistry and biology. The addition of the CVT compounds further enhances our growing portfolio of small molecule CDK inhibitors and is expected to inform our understanding of structure-activity relationships in this important area of cancer research. We are pleased to be working with a highly-regarded US biotechnology company like CV Therapeutics and look forward to a mutually-beneficial relationship."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News